Whereas all antidiabetic agents lower glucose levels, some drug classes primarily target insulin sensitivity and others primarily target β-cell function.9 Specifically, metformin and thiazolidinediones primarily act by improving insulin sensitivity, whereas drug classes like α-glucosidase inhibitors, sulfonylureas, and GLP1 receptor agonists primarily act by increasing insulin secretion from the β cells.9 How these drug classes influence risk of the different stroke subtypes should be explored further in future research. The gene discussed is INS; the disease is stroke disorder.